Press Esc to close

Welcome to Money Morning - Only the News You Can Profit From.

Close

This Says Our Favorite Biotech Is Off to the Races

Shares of a promising biotech we recommended back in February 2013 – jumped as much as 27% to a three-month high of $14.20 yesterday after the company said a new cancer drug met its main goal in a midstage clinical trial.

Its shares backtracked a bit as the day progressed but still closed 17.6% higher for the session. These shares have advanced 361% since we first told you about them. The stock has generated a peak gain of 456%, making it one of the 31 recommendations we’ve made to you that have doubled or better since we launched Private Briefing in August 2011. (More on that later…)

  • Featured Story

    Buy, Sell or Hold: Oracle Corp. (NASDAQ: ORCL) is The Last Cash Cow

    Today marks my 117th and final article at Money Morning.

    Viewed as a portfolio, I'm proud that those 117 calls are up on average. Before we get into my take on Oracle Corp (NASDAQ: ORCL) I'd like to take a look back over years.

    The 2010 picks have held up nicely with 12 positive and just six negative, for a 10 percent positive return on average, as of this writing.

    The hot long ideas of 2011 turned out to be El Paso (NYSE: EP) and Sturm, Ruger & Co. (NYSE: RGR). El Paso is up 48% while Ruger is up 78%.

    So far in 2012 the column's best sell idea, Petrobras (NYSE ADR: PBR), has dropped 15% since January 24. Our Jan. 30 "Buy" recommendation on Apple (NASDAQ: AAPL) is up 32%.

    It's been a great run and my thanks again to the entire Money Morning staff for the opportunity.

    Now, let's talk about the one company that Buy, Sell or Hold has not covered yet but I believe is deserving of the column's final recommendation: Oracle Corp (NASDAQ: ORCL).

    To continue reading, please click here...

    Read More...
  • Nasdaq: ORCL stock price